This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 1977 Jul-Aug;18(4):309-17.

doi: 10.1016/0010-440x(77)90001-3.

Receptor sensitivity modification (RSM)--a new paradigm for the potential treatment of some hormonal and transmitter disturbances

PMID: 194744
DOI: 10.1016/0010-440x(77)90001-3

Case Reports

Receptor sensitivity modification (RSM)--a new paradigm for the potential treatment of some hormonal and transmitter disturbances

A J Friedhoff. Compr Psychiatry. 1977 Jul-Aug.

. 1977 Jul-Aug;18(4):309-17.

doi: 10.1016/0010-440x(77)90001-3.

Author

PMID: 194744
DOI: 10.1016/0010-440x(77)90001-3

No abstract available

PubMed Disclaimer

Similar articles

Levodopa and receptor sensitivity modification in tardive dyskinesia.
Casey DE, Gerlach J, Bjørndal N. Casey DE, et al. Psychopharmacology (Berl). 1982;78(1):89-92. doi: 10.1007/BF00470596. Psychopharmacology (Berl). 1982. PMID: 6128757
Receptor-cell sensitivity modification (RSM) as a model for pathogenesis and treatment of tardive dyskinesia.
Friedhoff AJ, Rosengarten H, Bonnet K. Friedhoff AJ, et al. Psychopharmacol Bull. 1978 Oct;14(4):77-9. Psychopharmacol Bull. 1978. PMID: 704769 No abstract available.
Use of dopamine receptor agonists to reduce dopamine receptor number as treatment for tardive dyskinesia.
Alpert M, Friedhoff AJ, Diamond F. Alpert M, et al. Adv Neurol. 1983;37:253-8. Adv Neurol. 1983. PMID: 6134444 Clinical Trial. No abstract available.
New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
Hadj Tahar A, Grondin R, Grégoire L, Calon F, Di Paolo T, Bédard PJ. Hadj Tahar A, et al. Adv Neurol. 2003;91:51-64. Adv Neurol. 2003. PMID: 12442663 Review. No abstract available.
Emerging drugs for levodopa-induced dyskinesia.
Al Dakheel A, Beaulieu-Boire I, Fox SH. Al Dakheel A, et al. Expert Opin Emerg Drugs. 2014 Sep;19(3):415-29. doi: 10.1517/14728214.2014.955014. Epub 2014 Aug 22. Expert Opin Emerg Drugs. 2014. PMID: 25146568 Review.

See all similar articles

Cited by

Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.
El-Sayeh HG, Rathbone J, Soares-Weiser K, Bergman H. El-Sayeh HG, et al. Cochrane Database Syst Rev. 2018 Jan 18;1(1):CD000458. doi: 10.1002/14651858.CD000458.pub3. Cochrane Database Syst Rev. 2018. PMID: 29342497 Free PMC article.
Pharmacological options for the management of dyskinesias.
Shale H, Tanner C. Shale H, et al. Drugs. 1996 Dec;52(6):849-60. doi: 10.2165/00003495-199652060-00006. Drugs. 1996. PMID: 8957155 Review.
Levodopa-responsive dystonia, parkinsonism, and treatment-resistant schizoaffective disorder in Williams syndrome.
Reyes NGD, Bendahan N, Swinkin E, Lang AE, Bassett AS. Reyes NGD, et al. Neurol Sci. 2025 Jan;46(1):463-468. doi: 10.1007/s10072-024-07705-3. Epub 2024 Jul 18. Neurol Sci. 2025. PMID: 39023712 Free PMC article.
The effect of chronic bromocriptine and L-dopa on spiperone binding and apomorphine-induced stereotypy.
Globus M, Bannet J, Lerer B, Belmaker RH. Globus M, et al. Psychopharmacology (Berl). 1982;78(1):81-4. doi: 10.1007/BF00470594. Psychopharmacology (Berl). 1982. PMID: 6815701
Levodopa and receptor sensitivity modification in tardive dyskinesia.
Casey DE, Gerlach J, Bjørndal N. Casey DE, et al. Psychopharmacology (Berl). 1982;78(1):89-92. doi: 10.1007/BF00470596. Psychopharmacology (Berl). 1982. PMID: 6128757

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science